title: DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity.
abstract: BACKGROUND
  Gene-based vaccination using prime/boost regimens protects animals and humans against malaria, inducing cell-mediated responses that in animal models target liver stage malaria parasites. We tested a DNA prime/adenovirus boost malaria vaccine in a Phase 1 clinical trial with controlled human malaria infection.
  
  
  RESULTS
  The vaccine regimen was three monthly doses of two DNA plasmids (DNA) followed four months later by a single boost with two non-replicating human serotype 5 adenovirus vectors (Ad). The constructs encoded genes expressing P. falciparum circumsporozoite protein (CSP) and apical membrane antigen-1 (AMA1). The regimen was safe and well-tolerated, with mostly mild adverse events that occurred at the site of injection. Only one AE (diarrhea), possibly related to immunization, was severe (Grade 3), preventing daily activities. Four weeks after the Ad boost, 15 study subjects were challenged with P. falciparum sporozoites by mosquito bite, and four (27%) were sterilely protected. Antibody responses by ELISA rose after Ad boost but were low (CSP geometric mean titer 210, range 44-817; AMA1 geometric mean micrograms/milliliter 11.9, range 1.5-102) and were not associated with protection. Ex vivo IFN-γ ELISpot responses after Ad boost were modest (CSP geometric mean spot forming cells/million peripheral blood mononuclear cells 86, range 13-408; AMA1 348, range 88-1270) and were highest in three protected subjects. ELISpot responses to AMA1 were significantly associated with protection (p = 0.019). Flow cytometry identified predominant IFN-γ mono-secreting CD8+ T cell responses in three protected subjects. No subjects with high pre-existing anti-Ad5 neutralizing antibodies were protected but the association was not statistically significant.
  
  
  CONCLUSIONS
  The DNA/Ad regimen provided the highest sterile immunity achieved against malaria following immunization with a gene-based subunit vaccine (27%). Protection was associated with cell-mediated immunity to AMA1, with CSP probably contributing. Substituting a low seroprevalence vector for Ad5 and supplementing CSP/AMA1 with additional antigens may improve protection.
  
  
  BACKGROUND
  ClinicalTrials.govNCT00870987.
authors: US Military Malaria Vaccine Program, Naval Medical Research Center, Silver Spring, Maryland, United States of America.
authors: Ilin
authors: I
authors: Chuang
authors: Martha
authors: M
authors: Sedegah
authors: Susan
authors: S
authors: Cicatelli
authors: Michele
authors: M
authors: Spring
authors: Mark
authors: M
authors: Polhemus
authors: Cindy
authors: C
authors: Tamminga
authors: Noelle
authors: N
authors: Patterson
authors: Melanie
authors: M
authors: Guerrero
authors: Jason W
authors: JW
authors: Bennett
authors: Shannon
authors: S
authors: McGrath
authors: Harini
authors: H
authors: Ganeshan
authors: Maria
authors: M
authors: Belmonte
authors: Fouzia
authors: F
authors: Farooq
authors: Esteban
authors: E
authors: Abot
authors: Jo Glenna
authors: JG
authors: Banania
authors: Jun
authors: J
authors: Huang
authors: Rhonda
authors: R
authors: Newcomer
authors: Lisa
authors: L
authors: Rein
authors: Dianne
authors: D
authors: Litilit
authors: Nancy O
authors: NO
authors: Richie
authors: Chloe
authors: C
authors: Wood
authors: Jittawadee
authors: J
authors: Murphy
authors: Robert
authors: R
authors: Sauerwein
authors: Cornelus C
authors: CC
authors: Hermsen
authors: Andrea J
authors: AJ
authors: McCoy
authors: Edwin
authors: E
authors: Kamau
authors: James
authors: J
authors: Cummings
authors: Jack
authors: J
authors: Komisar
authors: Awalludin
authors: A
authors: Sutamihardja
authors: Meng
authors: M
authors: Shi
authors: Judith E
authors: JE
authors: Epstein
authors: Santina
authors: S
authors: Maiolatesi
authors: Donna
authors: D
authors: Tosh
authors: Keith
authors: K
authors: Limbach
authors: Evelina
authors: E
authors: Angov
authors: Elke
authors: E
authors: Bergmann-Leitner
authors: Joseph T
authors: JT
authors: Bruder
authors: Denise L
authors: DL
authors: Doolan
authors: C Richter
authors: CR
authors: King
authors: Daniel
authors: D
authors: Carucci
authors: Sheetij
authors: S
authors: Dutta
authors: Lorraine
authors: L
authors: Soisson
authors: Carter
authors: C
authors: Diggs
authors: Michael R
authors: MR
authors: Hollingdale
authors: Christian F
authors: CF
authors: Ockenhouse
authors: Thomas L
authors: TL
authors: Richie
mesh_terms: D000260:Adenoviruses, Human / Q000235:genetics* / Q000276:immunology; D000293:Adolescent; D000328:Adult; D000953:Antigens, Protozoan / Q000235:genetics* / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D005260:Female; D006801:Humans; D007111:Immunity, Cellular; D007371:Interferon-gamma / Q000276:immunology; D017780:Malaria Vaccines / Q000009:adverse effects / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use*; D016778:Malaria, Falciparum / Q000276:immunology / Q000469:parasitology / Q000517:prevention & control*; D008297:Male; D008565:Membrane Proteins / Q000235:genetics* / Q000276:immunology; D008875:Middle Aged; D010963:Plasmodium falciparum / Q000235:genetics* / Q000276:immunology; D015800:Protozoan Proteins / Q000235:genetics* / Q000276:immunology; D019444:Vaccines, DNA / Q000009:adverse effects / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D000953:Antigens, Protozoan; D017780:Malaria Vaccines; D008565:Membrane Proteins; D015800:Protozoan Proteins; D019444:Vaccines, DNA; C090077:apical membrane antigen I, Plasmodium; C041595:circumsporozoite protein, Protozoan; D007371:Interferon-gamma